echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Chinese scholars from Lancet sub-Journal: New type of immunotherapy greatly prolongs the survival time of patients with liver cancer!

    Chinese scholars from Lancet sub-Journal: New type of immunotherapy greatly prolongs the survival time of patients with liver cancer!

    • Last Update: 2021-06-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Primary liver cancer is abbreviated as liver cancer, which can be divided into three types: hepatocellular carcinoma, intrahepatic cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma
    .


    China is the country with the largest number of incidences and deaths of liver cancer in the world


    Primary liver cancer is abbreviated as liver cancer, which can be divided into three types: hepatocellular carcinoma, intrahepatic cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma


    According to the latest global cancer burden data released by the WHO International Agency for Research on Cancer in 2020 , China 's primary liver cancer incidence rate in China in 2020 ranks 5th in malignant tumors, and the mortality rate ranks 2nd.


    Although the diagnosis and treatment technology of liver cancer has made great progress in recent years , the overall 5- year net survival rate of liver cancer patients in China has not improved significantly, and it lags far behind Europe, the United States, and even South Korea, Japan and other countries
    .


    Therefore, only by scientifically understanding the risk factors of liver cancer, identifying the high-risk groups of liver cancer, and standardizing the monitoring program, can the early detection, diagnosis and treatment of liver cancer be achieved, and the survival rate of liver cancer patients can be effectively improved


    Despite recent liver cancer diagnosis technology it has made great progress, but in our country, liver cancer patients in general clinics in our country, patients with liver cancer in general in our country, patients with liver cancer overall 5 5 -year survival rate was no significant net increase, far behind Europe and even South Korea, Japan and other countries


    Hepatitis B virus (HBV hepatitis B virus (HBV ) infection is the main cause of the high burden of liver cancer in China


    This randomized, open-label Phase 2-3 study was conducted at 50 clinical sites
    in China .


    Aged 18 years or older with histologically or cytologically confirmed diagnosis or clinical patients with unresectable or metastatic liver cancer, not previously received systemic therapy, baseline eastern Cooperative Oncology Group ( ECOG ) performance status of 0 or 1 patients Eligible to be included


    This randomized, open-label Phase 2-3 study was conducted at 50 clinical sites


    Compared with the standard treatment of sorafenib (red line), the progression-free survival (A) and overall survival (B) of the cintilimumab combined with IBI305 group (blue line)

    Compared with the standard treatment of sorafenib (red line), the progression-free survival (A) and overall survival (B) of the cintilimumab combined with IBI305 group (blue line)

    During 2019.
    02.
    11-2020.
    01.
    15 , 595 patients were
    recruited .


    Twenty-four people were directly selected for the Phase 2 safety run-in period, and 571 people were randomly assigned to the cintilimer - bevacizumab biosimilar ( n=380 ) or sorafenib ( n=191 )


    During 2019.


    Sim for Limo - bevacizumab group and biosimilars median follow-up time sorafenib group were 10.


    In the first-line treatment of Chinese patients with unresectable HBV-related hepatocellular carcinoma, Sintilimox plus IBI305 showed obvious advantages in overall survival and progression-free survival
    .


    This combined treatment program can provide a new treatment option for such patients
    .

    In the first-line treatment of Chinese patients with unresectable HBV-related hepatocellular carcinoma, Sintilimox plus IBI305 showed obvious advantages in overall survival and progression-free survival
    .
    This combined treatment program can provide a new treatment option for such patients
    .
    In the first-line treatment of Chinese patients with unresectable HBV-related hepatocellular carcinoma, Sintilimox plus IBI305 showed obvious advantages in overall survival and progression-free survival
    .
    This combined treatment program can provide a new treatment option for such patients
    .

     

     

    references:

    references:

    Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study.
    https://doi.
    org/10.
    1016/S1470-2045(21)00252 -7

    Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study.
    https://doi.
    org/10.
    1016/S1470-2045(21)00252 -7 Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.